cyrilzakka/clinical-trials huggingface dataset:
Comparative Study on the Effectiveness of Plyometric PU and Swiss Ball PU in Badminton Players

The aim of this study is to find out the comparative effect of plyometric push up and swiss ball push up in the management of throwing distance and accuracy among badminton player.

In previous researches, little literature is available regarding comparison of the effectiveness of plyometric push-up and Swiss ball push-up specifically in the management of throwing distance in badminton players. There is a dire need to explore the comparative effects of these two training methods within the context of badminton. Moreover, Further studies exploring different approaches for throwing accuracy in badminton players are required in the existing researches.

Eligibility Criteria:
Inclusion Criteria:

* Both Male and Females
* Age 16-30 years
* Sporting activity of minimum 40 minutes thrice a week
* Subjects being engaged in sports that require athlete's arm to be above shoulder height on a repetitive basis during throwing.

Exclusion Criteria:

* Spinal deformity
* Cervical spine pathology
* Glenohumeral subluxation
* Any recent upper limb fracture
* Recent Rotator cuff tear
* Bone disease
* Glenohumeral dislocation
A Study in Japan of the Safety and Antiviral Activity With Chronic Hepatitis B Infection

The objectives of this study are to demonstrate that entecavir has antiviral activity with undetectable at Week 48, and to assess the safety and the pharmacokinetic in Japanese patients given entecavir at each dose of 0.1 and 0.5 mg for 52 weeks


Eligibility Criteria:
Inclusion Criteria:

* Documentation of chronic hepatitis B infection by ALL of the following:

  1. Positive for HBsAg OR, negative for IgM core antibody and confirmation of chronic hepatitis B on liver biopsy
  2. Positive for HBeAg OR negative for HBeAg
  3. Documented HBV Viremia on 2 or more occasions and at screening visit: Viremia on sample drawn AND HBV DNA of ≥ 10\*5\* copies/mL by PCR assay at the screening visit
* ALT in the range of 1.3 to 10 x ULN
A Biopharmaceutics Study to Assess the Pharmacokinetics of Single Oral and IV Doses of Olorofim

This is a Phase I, single-centre, randomised, open-label, crossover study in 24 healthy subjects. Twelve subjects will each receive olorofim as a single IV infusion, single oral dose (fasted) and single oral dose (fed) and 12 subjects will each receive olorofim orally as intact tablets and via NG tube


Eligibility Criteria:
Inclusion Criteria:

* males or females of any ethnic origin between 18 and 55 years of age
* subjects weighing between 50 and 100 kg, with a body mass index (BMI) between 18 and 30 kg/m2.
* subjects in good health, as determined by a medical history, physical examination, 12-lead electrocardiogram (ECG) and clinical laboratory evaluations

Exclusion Criteria:

* Male subjects (or their partners) who are not willing to use appropriate contraception during the study and for 3 months after end of dosing.
* Female subjects who are pregnant or lactating.
* Subjects who have received any prescribed systemic or topical medication within 14 days of first dose administration
* Subjects who have used any non-prescribed systemic or topical medication within 7 days of first dose administration
* Subjects who have received any medications, including St John's Wort, known to chronically alter drug absorption or elimination processes within 30 days of first dose administration
* Subjects with or history of clinically significant neurological, gastrointestinal, renal, hepatic, cardiovascular, psychiatry, respiratory, metabolic, endocrine, ocular haematological or other major disorders as determined by the investigator
The Effect of QVA149 on Health Related Quality of Life in Patients With Chronic Obstructive Pulmonary Disease (COPD)

This study will assess the efficacy and safety of QVA149 compared to tiotropium plus formoterol in patients with moderate to severe COPD.


Eligibility Criteria:
Inclusion Criteria:

* Male or female adults aged ≥ 40 yrs
* Patients with moderate to severe chronic obstructive pulmonary disease (GOLD 2010 guidelines)
* Smoking history of at least 10 pack years
* Post-bronchodilator FEV1 \< 80% and ≥30% of the predicted normal value and post-bronchodilator FEV1/FVC (forced vital capacity) \<70%

Exclusion Criteria:

* Pregnant women or nursing mothers or women of child-bearing potential not using adequate contraception
* Patients with a history of long QT syndrome
* Patients with Type I or uncontrolled Type II diabetes
* Patients who have had a COPD exacerbation or respiratory tract infection within 6 weeks prior to screening
* Patients with any history of asthma
* Patients with pulmonary lobectomy, lung volume reduction surgery, or lung transplantation
* Patients with concomitant pulmonary disease
* Patients requiring long term oxygen therapy (\>15 h a day)

Other protocol-defined inclusion/exclusion criteria may apply.
IPACK Block After Total Knee Arthroplasty

Adductor canal block (ACB) is a peripheral nerve blockade technique that provides good pain control in patients undergoing total knee arthroplasty (TKA) which however does not relieve posterior knee pain. The recent technique of an ultrasound-guided local anesthetic infiltration of the interspace between popliteal artery and the capsule of posterior knee (IPACK) has shown promising results in providing significant posterior knee analgesia without affecting the motor nerves. The hypothesis was that the combination of ACB + IPACK will provide better pain relief and improve knee function in the immediate postoperative period compared to ACB alone.

This is a prospective, randomized and double blinded study

All patients received :

* Pregabalin 150 mg preoperatively 12 h before the surgery.
* Single-shot spinal anesthesia with 10 to 12 mg of bupivacaine 0.5% and 2.5ug sufentanil patients were randomly allocated to receive:
* Group 1: IPACK + ACB single shoot
* Group 2: contineous ACB For group 1: IPACK was realized after spinal anesthesia with 40 ml ropivacaine 0.2% All patients received ACB in the immediate postoperative period with 20 ml ropivacaine 0.2%

Post operative analgesia included:

* Paracetamol 1g IV every 6 hours
* Diclofenac sodium (50mg) 1 tablet x 2 per day
* Pregabalin 150 mg given orally once daily for a period of 4 weeks.
* PCA morphine (Patient Controlled Analgesia), as a rescue analgesia,
* Continuous ACB catheter for 48H with :

  4 ml per hour 0.2% ropivacaine in group 2 4 ml per hour saline in group 1

Eligibility Criteria:
Inclusion Criteria:

* primary total knee arthroplasty under spinal anesthesia

Exclusion Criteria:

* Contraindication or refusal to regional anesthesia
* Contraindication to non steroidal anti inflammatory (NSAID's)
* Allergy to opioids
* Allergy to paracetamol
* Creatinine clearance \< 30ml/min
* Weight\<50 kg or \>100kg
Positioning in Wheelchair Bound Patients

The choice of the most suitable chair as well as the improvement of the patient's positioning on this wheelchair is important to limit the discomfort, to prevent the risks of bedsores, the pains related to prolonged sitting and finally to support the interaction of the patient with its environment. The goal of this prospective, longitudinale, monocentric study is to evaluate the impact of standardized positioning in wheelchair-bound patients at risk of slipping.

The main questions on the positioning actions are:

* their actions impact of positioning actions on shear forces
* their impact on sliding in the chair
* their impact on the feeling of discomfort in the chair
* their impact on the caregivers' feelings about the patient's difficulties (eating, transfers, sliding)

Participation in this study will involve an increase in the number of transfers required for shear sheet placement and removal, as well as the time required for ischial measurement and the time to complete the (Tool for Assessing Wheelchair disComfort) TAWC questionnaire.


Eligibility Criteria:
Inclusion Criteria:

* Patient hospitalized for a minimum of 9 days (minimum 48-hour reflection period after information)
* Patient aged between 18 and 80 years,
* Patient with a sitting time in a wheelchair \> or equal to 1 hour,
* Patient with a neurological condition : multiple sclerosis, stroke, spinal cord injury, Parkinson disease, neurodegenerative diseases...
* Patient informed of the study and having given his written consent,

Non inclusion Criteria:

* Cognitive disorders that do not allow the understanding of instructions
* Patient with a pressure sore
* Pregnant or breastfeeding woman
* Patient under legal protection
HILT or Conventional Combined Physical Therapy, in the Management of Hemiplegic Shoulder Pain

Background: Hemiplegic shoulder pain is one of the most common complications after a stroke. There are many treatment strategies for this complication. High-intensity laser therapy (HILT) is a new treatment option, and we aimed to compare the effectiveness of conventional electrotherapy agents and HILT in this study.

Patients and methods: Participants (N = 42) were randomized into the HILT (n = 21) and TENS+US (n = 21) groups. Group 1 received 3 sessions of HILT per week for 3 weeks in addition to a therapeutic exercise program that performed 5 sessions per week for 3 weeks. Group 2 received conventional physical therapy and a therapeutic exercise program for HSP of 5 sessions per week for 3 weeks. Patients were assessed before and after treatment on the on the 6th week for radiological evaluation with ultrasonography and for clinical parameters with VAS, AMAT, MRS, and FIQ scores.


Eligibility Criteria:
Inclusion Criteria:

* Diagnosed case of HSP,
* Age ≥18,
* First-ever unilateral stroke,
* Visual analog scale (VAS) ≥30 mm,
* Time since stroke ≥6 months,
* Time since last local intervention treatment \>6 months.

Exclusion Criteria:

* A history of shoulder pain prior to stroke;
* An unstable medical condition or uncontrolled systemic diseases (such as respiratory failure, congestive heart failure, liver and kidney dysfunction, or any other disorders affecting neuromuscular function);
* Bilateral hemiplegia;
* Cardiac pacemakers;
* Disturbance of awareness, severe visual and cognitive impairment, Mini-Mental State Examination score: \<23 points
Effectiveness of Oral Management Strategies on Improving Oral Frailty and Oral Bacteria

The aim of this study is to examine the effectiveness of nurse-driven oral management for improvements of oral frailty, and oral bacteria pneumonia patients with oral frailty using a randomized controlled trial (RCT) design. Hospitalized pneumonia patients (N = 90) will be randomized into three groups (oral management, oral care, and standard of care). The primary outcomes include the oral frailty measures determined by seven-item included oral hygiene, oral dryness, occlusion force, tongue-lip motor function, tongue pressure, mastication function, and swallowing function. Saliva samples were collected from the oral cavity before the bacterial culture was performed in the laboratory. Oral frailty measures and the presence of bacterial exposure were evaluated at baseline (1st day), on days 5, and at the time of discharge. The investigators will perform statistical analyses according to the intention-to-treat principle. All missing values will be imputed using the last value carry-forward method. The between-group differences will be examined using a mixed model in which group and time interaction will be included. This study finding could provide oral management strategies that could improve oral frailty and decrease oral bacteria for preventing recurrent pneumonia infection among middle-aged and older adults with pneumonia.

The inclusion criteria will be as follows: (1) patients should be ≥ 50 years old; (2) patients' oral frailty should have been diagnosed with pneumonia, and (3) patients should have a Glasgow coma index of 15 points and be able to cooperate. Alternatively, the exclusion criteria will be as follows: (1) people with healthcare-related pneumonia; (2) those with head and neck cancer; or (3) those having an abnormal oral structure.

Eligibility Criteria:
Inclusion Criteria:

* Older than 50 years of age and equal
* Having mental clarity (Glasgow coma scale: 15)

Exclusion Criteria:

* A brief hospitalization (≤ 3 days) for non-acute care, such as uncomplicated elective percutaneous coronary intervention;
* Acute psychiatric syndromes;
* Received dental treatment in the last 6 months.
Open Versus Endoscopic Surgery of Craniomaxillofacial (CMF) Condylar Neck Fractures

This study is a comparison of open surgery versus an endoscopic approach in condylar neck fractures; it will look at functional outcome, cosmetic outcome and patient satisfaction.

The primary outcome measure is functional outcome based on the Helkimo dysfunction index.

Eligibility Criteria:
Inclusion Criteria:

* Adult patient \> 18 years
* Unilateral or bilateral fracture of the condylar neck
* Inclination of the condyle \> 30%
* Severe dislocation
* Severe pain upon palpation/movement
* Eligible for open reduction and internal fixation of the fracture
* Amenable to endoscopic as well as open surgery

Exclusion Criteria:

* High or intracapsular condylar neck fracture
* Very low fractures that can be reduced intraorally
* CMF malfunctioning
* Drug or alcohol abuse
* General or local conditions that adversely affect bone physiology
* Physical or mental incapacity to sign informed consent
Investigation of the Optimal Duration of Neoadjuvant Therapy for Resectable Pancreatic Cancer

Investigating the Optimal Duration of Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer to Determine the True Surgical Indication.


Eligibility Criteria:
Inclusion Criteria:

* radiologically resectable pancreatic cancer patients

Exclusion Criteria:

* a body weight loss of greater than 10% during the six months prior to surgery, the presence of distant metastases, or seriously impaired function of vital organs due to respiratory, renal, or heart disease
Effects of Osteopathic Technique on Autonomic Nervous System Activity

Cranial osteopathic manipulation technique for brain and cranial nerve function, known as the fourth ventricle compression (CV4), has been recognized. Rib raising (RR), aimed at reducing rib restriction and conditions associated with sympathetic hypertonia, is also employed. This study aimed to assess, in about 109 healthy individuals, the effects of osteopathic techniques (CV4 and RR) on autonomic nervous system (ANS) activity, as measured by heart rate variability (HRV).

In this planned study, 109 healthy subjects will be randomly assigned to one of three groups. A total of 90-100 participants are expected to complete all stages of the study, and their data will be used in the final analysis. The first experimental group will undergo three 30-minute sessions of osteopathic therapy, including the CV4 and RR techniques. The second group will receive three 30-minute sessions of the CV4 technique alone. The placebo group will undergo a sham procedure using an ultrasound transducer. To evaluate the impact of these osteopathic techniques on autonomic nervous system (ANS) function, Heart Rate Variability (HRV) will be measured using an EEG/HRV/RSA Infiniti 8 device, ProComp Infiniti encoder, and Biograph Infiniti and Physiology Suit software. Measurements will be conducted in a seated position over a 5-minute duration.

Eligibility Criteria:
Inclusion Criteria:

* Age between 20 and 60 years.
* Subjects not currently undergoing any form of rehabilitation, physiotherapy, or osteopathy

Exclusion Criteria:

* Unstable arrhythmia in the patient's history and symptoms related to chest organs (retrosternal pain, difficulty breathing).
* Pregnancy.
* Menstruation.
* Smoking.
* Symptoms suggestive of disorders related to bowel obstruction (bloating with pain, vomiting, diarrhea).
* Surgical treatment in the head.
* Neurological diseases.
* Back and peripheral joint pain, trauma, and musculoskeletal dysfunction in the last 12 months.
* Having undergone physiotherapy or osteopathy treatment within the last month, regardless of the reason
The Relationship Between Osteoporosis and Chronic Oral Anticoagulation Therapy With Warfarin

The purpose of this study is to determine if osteoporosis is an unrecognized complication of chronic anticoagulation with warfarin.


Eligibility Criteria:
Inclusion Criteria:

* Patients on warfarin that have had BMD within a year

Exclusion Criteria:

* Patients on bisphosphates, SERMS, anticonvulsants, estrogens, androgens, calcitonin, hctz and thyroid hormone replacement
Fluid Status of Outpatients With Dyspnea

The purpose of this study is to determine the distribution of lung fluid status as reported by the IMED-4 system in patients presenting to the emergency department or urgent care facility with shortness of breath.


Eligibility Criteria:
INCLUSION CRITERIA

* Shortness of breath as the most prominent presenting symptom
* Age greater ≥ 45
* Willingness, ability, and commitment to participate in the study

EXCLUSION CRITERIA

* Patients with any active implantable medical device
* Patients who are pregnant or lactating
* Patients who have tattoos and or non-intact skin directly under the electrode position
* Patients who have had past allergic reactions to medical grade adhesives
* Patients that are dialysis dependent
* Patients who have had a lung lobectomy
* Patients in whom the shortness of breath presentation is due to obvious non HF cause such as acute chest trauma
* Patients who have received nitrates (sub-lingual, topical or IV), diuretics or vasopressors ≥ 1 hour prior to IMED-4 Recording
* Patients who decline to have their backs photographed with the IMED-4 device in position
* Patients who are receiving invasive or non-invasive positive airway pressure (PAP) ventilation prior to or following presentation to the ED (Self presentation or admission via EMS).
* Severe co-morbidity or poor general physical/mental health that, in the opinion of the Investigator, will not allow the subject to be a good study candidate (i.e. other disease processes, mental capacity, substance abuse, incarceration, shortened life expectancy, etc.)
Cognitive Oriented Strategy Training Augmented Rehabilitation (COSTAR) Treatment Approach for Stroke

Stroke is the most serious disabling condition in the United States and the developed world. Novel stroke rehabilitation approaches, such as task-specific training, have shown promise in improving an individual's recovery in the rehabilitation setting; however, evidence suggests that these improvements are not generalized or transferred to the home, community, or work settings. Thus, these interventions usually do not impact overall health and participation outcomes. This research study seeks to improve task-specific training as a stroke rehabilitation approach by integrating it with evidence-based cognitive-oriented strategies which have shown great promise as a way to address the limitations of task-specific training. The new treatment protocol is called Cognitive-Oriented Strategy Training Augmented Rehabilitation, or COSTAR. The hypothesis of this study is that COSTAR will result in more efficient functional skill acquisition, better long-term retention of skills learned, and generalization and transfer of skills learned to home, community, and work settings.


Eligibility Criteria:
Inclusion Criteria:

1. age 18 or older;
2. have completed all physician recommended rehabilitation and currently not receiving rehabilitation services;
3. at least one-month post-stroke;
4. have self-reported unmet functional goals; and
5. NIH Stroke Scale (NIHSS) total score of 2-12.

Exclusion Criteria:

1. have sustained a hemorrhagic stroke;
2. NIH Stroke Scale (NIHSS) aphasia rating of 1 or more (impaired speech);
3. MoCA cognitive screen score of less than 21 (impaired general cognitive ability);
4. neurological diagnoses other than stroke;
5. major psychiatric illness (bipolar disorder, OCD, panic disorder, PTSD, and/or borderline personality disorder);
6. no major depressive symptoms (PHQ-9 \< 20);
7. a score of 6 or less on the CIHI aphasia screen combined items 64 and 66;
8. terminal illness;
9. blindness; and
10. non-English speaking.
Vascular Effects of Rosiglitazone Versus Glyburide in Type 2 Diabetic Patients

The purpose of this study is to compare the vascular effects of two commonly used diabetes medications, rosiglitazone and glyburide in type 2 diabetic patients.

Rosiglitazone and glyburide are two commonly used diabetic medications that have both been shown to be effective in controlling blood glucose levels. Since they work in different ways, they may have different effects on the health of the blood vessels. This study will assess which medication is better at improving the health of the arteries separate from the blood glucose lowering effects. Artery health will be assessed non-invasively by ultrasound. Certain markers of atherosclerosis found in the blood will also be measured.

Eligibility Criteria:
Inclusion Criteria:

* Age 25-75 years
* Type 2 diabetes mellitus for less than or equal to 10 years
* Pre-screening HbA1c \> 6.5 %
* Screening 110 mg/dl \< fasting plasma glucose \< 240 mg/dl after 2 weeks of metformin 500 mg twice daily (b.i.d.)

Exclusion Criteria:

* Thiazolidinedione or sulfonylurea use in previous 30 days (may undergo washout period of 30 days)
* Known contraindications to use of thiazolidinedione or sulfonylurea
* Female patients must be postmenopausal, surgically sterile, or using adequate contraception
* Uncontrolled hyperlipidemia according to American Heart Association (AHA) guidelines
* Subcutaneous insulin use
* Elevated liver enzymes (2.5 times the upper limit of the reference range)
* Serum creatinine \>160 mmol/l
* Anemia (Hb \<11 g/dl for men or \<10 g/dl for women)
* Body mass index (BMI) \<22 or \>42 kg/m2
* History of ketoacidosis
* Angina/New York Health Academy class III/IV cardiac insufficiency
* Electrocardiographic evidence of marked left ventricular hypertrophy
* Uncontrolled hypertension according to AHA guidelines
* Hemoglobinopathy
Treatment Persistence of Biologics in Patients with PsA in Japan; Retrospective Cohort Study Using a Claims Database

This study was a retrospective non-interventional cohort study with secondary use of data from the Medical Data Vision (MDV) hospital-based database. The study setting was defined as follows:

* The inclusion period covered 01 February 2015 to 30 September 2020.
* The study period covered 01 August 2014 to 30 September 2021 inclusive.
* The index date was defined as the date of the first prescription of secukinumab or adalimumab within the inclusion period.
* The pre-index period was defined as the 6-month period before the index date (exclusive).
* Patients were followed until death, discontinuation of treatments of interest or end of the study period, whichever occurred first.


Eligibility Criteria:
Inclusion criteria:

* Having at least one biologic agent prescription of interest (secukinumab or adalimumab - princeps or biosimilars) recorded, in accordance with package insert, during the inclusion period (first prescription: index date).
* Having a confirmed diagnosis of PsA (the international classification of diseases, 10th revision \[ICD-10\]: L405) (at least 1 inpatient or outpatient claim without any doubtful flag) recorded during the pre-index period or at the index date.
* Being age 18 years or older at the index date.
* Having at least a 6-month pre-index period.

Bio-naive subgroup:

• Patients were considered as bio-naive if no record of any biologic agent prescriptions indicated for psoriasis or PsA (infliximab, adalimumab, certolizumab pegol, ustekinumab, risankizumab, guselkumab, secukinumab, ixekizumab, brodalumab - princeps or biosimilars) were retrieved during the pre-index period.

Exclusion Criteria:

* Having a biologic agent overdose (over 300 mg for secukinumab and over 80 mg for adalimumab) observed during the study period (off-label),
* Having at least one record of secukinumab (for secukinumab patients) or adalimumab (for adalimumab patients) retrieved during the pre-index period.